NEULAND LABORATORIES Financial Statement Analysis
|
||
The Revenues of NEULAND LABORATORIES have decreased by -5.24% YoY .
The Earnings Per Share (EPS) of NEULAND LABORATORIES has decreased by -13.32 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
NEULAND LABORATORIES Last 5 Annual Financial Results
[BOM: 524558|NSE : NEULANDLAB]
Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
---|---|---|---|---|---|
Revenues | ₹1,477 Cr | ₹1,559 Cr | ₹1,191 Cr | ₹951 Cr | ₹937 Cr |
Expenses | ₹1,154 Cr | ₹1,096 Cr | ₹919 Cr | ₹808 Cr | ₹790 Cr |
Operating Profit (Excl OI) | ₹323 Cr | ₹463 Cr | ₹272 Cr | ₹143 Cr | ₹147 Cr |
Other Income | ₹21 Cr | ₹13 Cr | ₹9.75 Cr | ₹2.08 Cr | ₹16 Cr |
Interest | ₹8.30 Cr | ₹14 Cr | ₹13 Cr | ₹13 Cr | ₹18 Cr |
Depreciation | ₹66 Cr | ₹60 Cr | ₹53 Cr | ₹49 Cr | ₹40 Cr |
Profit Before Tax | ₹346 Cr | ₹401 Cr | ₹216 Cr | ₹82 Cr | ₹105 Cr |
Profit After Tax | ₹260 Cr | ₹300 Cr | ₹164 Cr | ₹64 Cr | ₹81 Cr |
Consolidated Net Profit | ₹260 Cr | ₹300 Cr | ₹164 Cr | ₹64 Cr | ₹81 Cr |
Earnings Per Share (Rs) | ₹202.74 | ₹233.89 | ₹127.45 | ₹49.74 | ₹62.85 |
PAT Margin (%) | 17.61 | 19.25 | 13.73 | 6.71 | 8.61 |
ROE(%) | 18.54 | 26.38 | 17.84 | 7.85 | 10.79 |
ROCE(%) | 23.45 | 33.51 | 20.94 | 9.44 | 12.81 |
Total Debt/Equity(x) | 0.09 | 0.06 | 0.12 | 0.28 | 0.22 |
Key Financials |
||
Market Cap | : | ₹ 17,583.0 Cr |
Revenue (TTM) | : | ₹ 1,476.8 Cr |
Net Profit(TTM) | : | ₹ 260.1 Cr |
EPS (TTM) | : | ₹ 203.2 |
P/E (TTM) | : | 67.6 |
Industry Peers & Returns | 1W | 1M | 1Y |
NEULAND LABORATORIES | -2.9% | 14.8% | 64.8% |
SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 1.8% | 4.5% |
DIVIS LABORATORIES | -1.1% | 0.1% | 45.6% |
CIPLA | 3.8% | 1.2% | -1.1% |
TORRENT PHARMACEUTICALS | 2.2% | 11.7% | 11.7% |
DR REDDYS LABORATORIES | 1.4% | -3.3% | -7.2% |
MANKIND PHARMA | -1.7% | 13% | 22.9% |
ZYDUS LIFESCIENCES | 0.7% | -0.6% | -17.7% |
LUPIN | 1.5% | 1.3% | 7% |
NEULAND LABORATORIES Revenues
[BOM: 524558|NSE : NEULANDLAB]
Y-o-Y | -5.24 % |
5 Yr CAGR | 12.05 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹1,477 Cr | -5.24 | |
Mar2024 | ₹1,559 Cr | 30.84 | |
Mar2023 | ₹1,191 Cr | 25.25 | |
Mar2022 | ₹951 Cr | 1.51 | |
Mar2021 | ₹937 Cr | - |
NEULAND LABORATORIES Operating Profit
[BOM: 524558|NSE : NEULANDLAB]
Y-o-Y | -30.12 % |
5 Yr CAGR | 21.81 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹323 Cr | -30.12 | |
Mar2024 | ₹463 Cr | 70.17 | |
Mar2023 | ₹272 Cr | 90.61 | |
Mar2022 | ₹143 Cr | -2.86 | |
Mar2021 | ₹147 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -26.25 % |
5 Yr CAGR | 8.72 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 21.89% | -26.25 | |
Mar2024 | 29.68% | 30.06 | |
Mar2023 | 22.82% | 52.13 | |
Mar2022 | 15% | -4.28 | |
Mar2021 | 15.67% | - |
NEULAND LABORATORIES Profit After Tax
[BOM: 524558|NSE : NEULANDLAB]
Y-o-Y | -13.32 % |
5 Yr CAGR | 34.02 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹260 Cr | -13.32 | |
Mar2024 | ₹300 Cr | 83.51 | |
Mar2023 | ₹164 Cr | 156.21 | |
Mar2022 | ₹64 Cr | -20.85 | |
Mar2021 | ₹81 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -8.52 % |
5 Yr CAGR | 19.59 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 17.61 % | -8.52 | |
Mar2024 | 19.25 % | 40.20 | |
Mar2023 | 13.73 % | 104.62 | |
Mar2022 | 6.71 % | -22.07 | |
Mar2021 | 8.61 % | - |
NEULAND LABORATORIES Earnings Per Share (EPS)
[BOM: 524558|NSE : NEULANDLAB]
Y-o-Y | -13.32 % |
5 Yr CAGR | 34.02 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹203 | -13.32 | |
Mar2024 | ₹234 | 83.52 | |
Mar2023 | ₹127 | 156.23 | |
Mar2022 | ₹50 | -20.86 | |
Mar2021 | ₹63 | - |
NEULAND LABORATORIES Return on Capital Employed (ROCE)
[BOM: 524558|NSE : NEULANDLAB]
Y-o-Y | -30.02 % |
5 Yr CAGR | 16.32 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2025 | 23.45% | -30.02 | |
Mar2024 | 33.51% | 60.03 | |
Mar2023 | 20.94% | 121.82 | |
Mar2022 | 9.44% | -26.31 | |
Mar2021 | 12.81% | - |
NEULAND LABORATORIES Share Price vs Sensex
Current Share Price | : | ₹13,736.7 |
Current MarketCap | : | ₹ 17,583.0 Cr |
Updated EOD on | : | Jul 25,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NEULAND LABORATORIES | -2.9% |
14.8% |
64.8% |
SENSEX | -0.4% |
-1.6% |
1.3% |
NEULAND LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | 6.4% | 8.9% | 7.5% |
BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
BSE HEALTHCARE | 0.5% | 4% | 17% |
BSE 500 | -1.1% | -1.1% | 0% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MIDSMALL HEALTHCARE | 0.7% | 6.8% | 22.2% |
NIFTY 500 | -1.1% | -1.2% | 0.7% |
NIFTY500 MULTICAP INDIA MANUFACTURING 50:30:20 | -1.2% | 0.4% | 1.3% |
NIFTY TOTAL MARKET | -1.2% | -1.2% | 0.7% |
NIFTY500 MULTICAP 50:25:25 | -1.5% | -1% | 1.2% |
You may also like the below Video Courses
FAQ about NEULAND LABORATORIES Financials
How the annual revenues of NEULAND LABORATORIES have changed ?
The Revenues of NEULAND LABORATORIES have decreased by -5.24% YoY .
How the Earnings per Share (EPS) of NEULAND LABORATORIES have changed?
The Earnings Per Share (EPS) of NEULAND LABORATORIES has decreased by -13.32 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs